trending Market Intelligence /marketintelligence/en/news-insights/trending/h67quk0xrixobfrqt0l-_g2 content esgSubNav
In This List

Q Biomed closes $5.5M offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Q Biomed closes $5.5M offering

Q BioMed Inc. closed its public offering of 1,711,875 units for gross proceeds of $5.5 million.

Each unit, priced $3.20 apiece, consists of one common share and one warrant.

New York-based Q BioMed plans to use the net proceeds from the offering to commercialize its skeletal pain drug strontium chloride 89, file an investigational new drug application for phase 2/3 trial of its autism drug and for continued research and development of its liver cancer and glaucoma drugs.

Roth Capital Partners acted as lead placement agent while CIM Securities acted as co-lead placement agent for the offering.